
(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Islamic State group militants claim capture and execution of a Nigerian brigadier general - 2
Tatiana Schlossberg, JFK's granddaughter, dies at 35 after terminal cancer diagnosis - 3
Europe could get 42 more days of summer by the year 2100 due to climate change - 4
$2,000 tariff rebate checks? 50-year mortgages? Making sense of Trump's new 'affordability' proposals. - 5
Tatiana Schlossberg's diagnosis puts spotlight on leukemia: What to know
Rights groups condemn Israel Police decision to ban Sudan Genocide protests nationwide
Virtual Route d: A Survey of \Exploring On the web Stages\ Web Administration
Ryan Gosling responds to Deidre Hall's invitation to visit the 'Days of Our Lives' set: 'This is a very enthusiastic yes'
Benin coup thwarted by loyalist troops, president tells nation
10 Natural products to Remember for Your Eating routine for a Better You
Miss Thailand Pageant Contestant's Veneers Fall Out During Speech on Stage
Newly identified species of Tanzanian tree toad leapfrog the tadpole stage and give birth to toadlets
6 Web-based Course Stages for Successful Learning and Educating
RFK Jr. wants to scrutinize the vaccine schedule – but its safety record is already decades long












